Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Ocrelizumab in autoimmune diseases<br />
• Ocrelizumab is a humanized anti-CD 20 antibody<br />
– <strong>Roche</strong> is committed to studying B-cell therapy<br />
– <strong>Roche</strong> is studying ocrelizumab in rheumatoid arthritis, systemic lupus<br />
erythematosus (SLE), and multiple sclerosis (MS)<br />
• <strong>Roche</strong> and Genentech are conducting global Phase III program for RA<br />
– First study began in December 2006<br />
• Two global Phase III trials are being initiated in SLE (enrollment is expected to<br />
start in 4Q 2007)<br />
• <strong>Roche</strong> and Genentech are also studying ocrelizumab in relapsing-remitting MS<br />
– Next steps are underway; findings from “proof of concept” rituximab study<br />
are being evaluated<br />
64